Can a blood test tell who will respond to lung cancer immunotherapy?
NCT ID NCT07608835
First seen May 29, 2026 · Last updated Jun 20, 2026 · Updated 5 times
Summary
This study is collecting blood and tumor samples from 200 people with non-small cell lung cancer to find biological markers that predict whether immunotherapy will work. Researchers will compare samples taken before treatment and at the time the disease gets worse. The goal is to better understand why only about 40% of patients respond to current immunotherapies and to identify new targets for treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Rochigneux
RECRUITINGMarseille, Institut Paoli Calmettes, 13009, France
Contact Phone: •••-•••-••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could help doctors predict which lung cancer patients will benefit from immunotherapy and point toward new treatment targets.
What could go wrong
This is an observational study, not a treatment trial. It may not lead directly to new therapies, and the findings may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.